ANI's 2026 Revenue Target Moves to $1.1B, but Cortrophin Now Carries More Than Half the Burden

Rare Disease is becoming ANI's main valuation lens

ANI's 2026 setup is less diversified than in recent years. Management is aiming for $1.055 billion to $1.115 billion in total revenue while expecting Rare Disease to represent approximately 60% of total net revenues. That creates upside if the specialty shift holds, but it also means ANI is increasingly being judged as a Cortrophin-led story rather than a balanced drug company.

Why that mix shift matters

Cortrophin Gel is now the center of gravity. In 2025, it generated $347.8 million, and management's 2026 framework still points to $540 million to $575 million of Cortrophin Gel revenue. That makes it the anchor product, not just one asset among many.

The bull case is straightforward: if Rare Disease becomes the majority of sales, investors may be more willing to apply a specialty valuation. The bear case is just as clear: when one product is expected to carry more than half the revenue target, there is less room for error in demand, access, and commercial execution. Management is trying to widen that runway with a roughly 90-person sales force for acute gouty arthritis flares, but until that buildout shows sustained commercial returns, concentration will remain the core debate.

The 2026 target looks more credible because growth is already visible

The important part of the 2026 target is not just the revenue range. It is the operating momentum behind it.

Cortrophin is already scaling

In 2025, Cortrophin Gel produced $347.8 million of revenue, up 75.6% year over year, and Rare Disease as a segment grew 84.1%. That is evidence of growth already showing up in the financials, not just in the pitch.

Fourth-quarter Cortrophin revenue also reached $111.4 million, up 87.6%, which means the product entered 2026 from a position of strength rather than a cold start. That does not guarantee the ramp will continue, but it does make the target more credible than a purely forward-looking launch story.

Why the gout sales force matters

ANI is building a roughly 90-person sales force dedicated to acute gouty arthritis flares. The point of that push is to widen the funnel: reach more relevant prescribers, speed up adoption, and give new patients more commercial support from the start.

That matters because a larger sales team is only valuable if it translates into more prescriptions. If the gout buildout helps Cortrophin reach a broader part of its addressable market, it gives ANI a more durable path to the 2026 target instead of relying solely on existing specialty channels.

Generics and Other also still matter. In 2025, that segment generated $384 million in revenue, helping fund the Rare Disease buildout rather than leaving it to stand on faith alone.

What could break the 2026 story

The key question is no longer whether Cortrophin can grow. It is whether growth can hold up once pricing, reimbursement, and commercial execution become the main variables.

Concentration raises the stakes

In 2025, Rare Disease and Brands already accounted for 54.8% of revenue, and management expects Rare Disease to represent about 60% of 2026 sales. That is the upside setup. It is also the stress test.

When one franchise carries most of the revenue, every prescription matters more. Any wobble in demand or access has a bigger impact on the whole company.

Pricing support can help, but it does not remove the risk

ANI is leaning on access support to narrow the gap between list price and what patients actually pay. The company says its program can leave many eligible commercially insured patients paying as little as $0 out of pocket, after a cited 23.2% discount. But the underlying list-price difference is still meaningful: Acthar Gel is priced at $9,332.60 per mL versus Cortrophin Gel at $7,169.80 per mL.

That is why reimbursement matters so much now. If payer coverage tightens or assistance does not fully close the gap for enough patients, prescriptions could slow even if clinical demand remains healthy.

The latest quarter also shows why timing matters. First-quarter Cortrophin revenue was $75.1 million, up 42%, but management also flagged early-quarter seasonality effects tied to insurance reverifications. One soft quarter is not automatically thesis-breaking, but another weak quarter would make investors more skeptical of the ramp.

• Access: tighter payer rules or weaker coverage can slow a premium specialty product.
• Pricing support: higher assistance use can help volume, but it makes revenue quality harder to underwrite.
• Cadence: if growth stalls before the gout team shows sustained impact, the market may stop treating ANI as a specialty franchise and start treating it as a one-product story.

What investors should watch next

From here, the call is whether a company headed toward about 60% of 2026 sales from Rare Disease can scale cleanly enough to earn a higher multiple.

The cleanest positive signal is another quarter of clear, quarter-over-quarter Cortrophin progress. The clearest warning sign is simpler: a soft quarter that suggests the ramp is slipping just as expectations are getting tougher.

The near-term scorecard

Management has made the mid-2026 deployment of the gout team central to the story, as outlined on the first-quarter earnings call. So the next few quarters should answer a straightforward question: is this a normal launch rhythm, or is the growth curve starting to flatten?